{
    "clinical_study": {
        "@rank": "40011", 
        "arm_group": [
            {
                "arm_group_label": "Colesevelam", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Chenodeoxycholic acid", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Colesevelam + chenodeoxycholic acid", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to describe the physiological, pathophysiological and\n      potentially therapeutic implications of bile-induced glucagon-like peptide-1 (GLP-1)\n      secretion in human glucose homeostasis."
        }, 
        "brief_title": "Effect of Bile Acids on GLP-1 Secretion", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Type 2 Diabetes", 
            "Obesity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Obesity"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators hypothesize that even modest increments in endogenous GLP-1 secretion will\n      elicit important antidiabetic effects of GLP-1. To evaluate whether bile acids have such\n      effects, the investigators plan to perform intraduodenal infusion of two different bile\n      acids and placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients with type 2 diabetes\n\n        Inclusion Criteria:\n\n          -  danish caucasian ethnicity\n\n          -  normal haemoglobin\n\n          -  BMI > 25 kg/m2\n\n          -  HbA1c < 9%\n\n          -  informed consent\n\n        Exclusion Criteria:\n\n          -  liver disease(ALT and AST > upper reference limit)\n\n          -  gastrointestinal disease\n\n          -  liver and biliary tract disease\n\n          -  nephropathy (serum creatinine > 150 \u03bcM, and/or albuminuria)\n\n          -  treatment with insulin, glp-1 analogues and/ or DPP-4 inhibitors\n\n          -  treatment with medicine that can not be paused for 12 hours\n\n          -  previous abdominal surgery eg. cholecystectomy\n\n          -  BMI < 18,5 kg/m2 or > 35 kg/m2\n\n        Healthy Volunteers\n\n        Inclusion Criteria:\n\n          -  danish caucasian ethnicity\n\n          -  normal haemoglobin\n\n          -  HbA1c < 6,0 (American Diabetes Association guidelines)\n\n          -  informed consent\n\n        Exclusion Criteria:\n\n          -  liver disease(ALT and AST > upper reference limit)\n\n          -  gastrointestinal disease\n\n          -  liver and biliary tract disease\n\n          -  nephropathy (serum creatinine > 150 \u03bcM, and/or albuminuria)\n\n          -  treatment with medicine that can not be paused for 12 hours\n\n          -  previous abdominal surgery eg. cholecystectomy\n\n          -  BMI < 18,5 kg/m2 or > 35 kg/m2\n\n          -  first degree relatives diagnosed with diabetes\n\n          -  previously diagnosed with diabetes, or treated with antidiabetic agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666223", 
            "org_study_id": "H-1-2012-049"
        }, 
        "intervention": [
            {
                "arm_group_label": "Colesevelam", 
                "description": "Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.", 
                "intervention_name": "Colesevelam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Chenodeoxycholic acid", 
                "description": "1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.", 
                "intervention_name": "Chenodeoxycholic Acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "100 ml saline", 
                "intervention_name": "saline", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Colesevelam + chenodeoxycholic acid", 
                "description": "Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.", 
                "intervention_name": "Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bile Acids and Salts", 
                "Chenodeoxycholic Acid", 
                "Colesevelam"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Type 2 diabetes", 
            "GLP-1", 
            "Bile acid", 
            "TGR-5"
        ], 
        "lastchanged_date": "December 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hellerup", 
                    "country": "Denmark", 
                    "state": "Copenhagen"
                }, 
                "name": "Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "4", 
        "official_title": "Effect of Bile Acids in the Gut on GLP-1 Secretion in Healthy Subjects and Patients With Type 2 Diabetes", 
        "overall_official": {
            "affiliation": "Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen", 
            "last_name": "Morten Hansen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Denmark: The Danish National Committee on Biomedical Research Ethics", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in GLP-1", 
            "safety_issue": "No", 
            "time_frame": "At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes"
        }, 
        "reference": [
            {
                "PMID": "12419312", 
                "citation": "Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H, Tanaka K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002 Nov 15;298(5):714-9."
            }, 
            {
                "PMID": "8406158", 
                "citation": "Adrian TE, Ballantyne GH, Longo WE, Bilchik AJ, Graham S, Basson MD, Tierney RP, Modlin IM. Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut. 1993 Sep;34(9):1219-24."
            }, 
            {
                "PMID": "15721318", 
                "citation": "Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005 Apr 1;329(1):386-90."
            }, 
            {
                "PMID": "21521075", 
                "citation": "Rafferty EP, Wylie AR, Hand KH, Elliott CE, Grieve DJ, Green BD. Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R(-/-) mice. Biol Chem. 2011 Apr;392(6):539-46. doi: 10.1515/BC.2011.050. Epub 2011 Apr 27."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666223"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital, Gentofte, Copenhagen", 
            "investigator_full_name": "Morten Hansen", 
            "investigator_title": "MD, PhD Student", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in insulin", 
                "safety_issue": "No", 
                "time_frame": "At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes"
            }, 
            {
                "measure": "Change in C-peptide", 
                "safety_issue": "No", 
                "time_frame": "At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes"
            }, 
            {
                "measure": "Change in glucagon", 
                "safety_issue": "No", 
                "time_frame": "At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes"
            }, 
            {
                "measure": "Change in glucagon-like-peptide 2 (GLP-2)", 
                "safety_issue": "No", 
                "time_frame": "At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes"
            }, 
            {
                "measure": "Change in glucose-dependent insulinotropic polypeptide (GIP)", 
                "safety_issue": "No", 
                "time_frame": "At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes"
            }, 
            {
                "measure": "Change in peptide YY (PYY)", 
                "safety_issue": "No", 
                "time_frame": "At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes"
            }, 
            {
                "measure": "Change in oxyntomodulin", 
                "safety_issue": "No", 
                "time_frame": "At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes"
            }, 
            {
                "measure": "Change in bile acids", 
                "safety_issue": "No", 
                "time_frame": "At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes"
            }, 
            {
                "measure": "Change in gastrin", 
                "safety_issue": "No", 
                "time_frame": "At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes"
            }, 
            {
                "measure": "Change in CCK", 
                "safety_issue": "No", 
                "time_frame": "At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes"
            }, 
            {
                "description": "Evaluated by Visual Analog Scale (VAS)", 
                "measure": "Change in appetite, satiety and prospective food consumption", 
                "safety_issue": "No", 
                "time_frame": "At baseline, and 30, 60, 90, 120 and 180 minutes"
            }, 
            {
                "description": "Evaluated by ultrasound", 
                "measure": "Change in gallbladder volume", 
                "safety_issue": "No", 
                "time_frame": "-30, 0 (baseline), 30, 60, 120 og 180 minutes"
            }, 
            {
                "description": "Evaluated by indirect calorimetry", 
                "measure": "Change in basal metabolic rate", 
                "safety_issue": "No", 
                "time_frame": "At -30, 60 og 150 minutes"
            }, 
            {
                "description": "Evaluated by duodenal aspiration", 
                "measure": "Change in bile acid composition", 
                "safety_issue": "No", 
                "time_frame": "At -30, 0, 30, 60, 120 og 180 minutes"
            }
        ], 
        "source": "University Hospital, Gentofte, Copenhagen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Gentofte, Copenhagen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}